{"id":10583,"date":"2026-09-17T08:30:31","date_gmt":"2026-09-17T05:30:31","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=10583"},"modified":"2026-09-17T08:30:31","modified_gmt":"2026-09-17T05:30:31","slug":"anticoagulation-in-af-with-one-stroke-risk-factor-single-af-esc-2026","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/anticoagulation-in-af-with-one-stroke-risk-factor-single-af-esc-2026\/","title":{"rendered":"Anticoagulation in AF With One Stroke Risk Factor | SINGLE-AF | ESC 2026"},"content":{"rendered":"<p>Anticoagulation in AF With One Stroke Risk Factor | SINGLE-AF | ESC 2026<\/p>\n<p>Source:NEJM\u060c<br \/>\nMedscape , Sep 15, 2026. | ESC 2026<\/p>\n<p>\u2022\u2060 \u20601,803 intermediate-risk AF patients: CHA\u2082DS\u2082-VASc 1 in men or 2 in women \u2014: DOAC vs no anticoagulation; follow-up ~2 years.<br \/>\n\u2022\u2060 \u2060Primary outcome: 0.5% vs 1.5%; ischemic stroke 3 vs 10; major bleeding 3 vs 4.<br \/>\n\u2022\u2060 \u2060Relative benefit looks substantial, but absolute benefit is small: only ~1 event prevented per 100 patients treated for 2 years (NNT \u2248100).<br \/>\n\u2022\u2060 \u2060With only 3 vs 10 strokes, the result is statistically fragile\u2014a change of only 1\u20132 events could alter significance.<br \/>\n\u2022\u2060 \u2060Take-home: DOAC can further reduce an already-low stroke risk, but the absolute gain is small ; in AF with only one stroke risk factor, this supports individualized shared decision-making rather than automatic anticoagulation.<\/p>\n<p><a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2607978\">https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2607978<\/a><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Anticoagulation in AF With One Stroke Risk Factor | SINGLE-AF | ESC 2026 Source:NEJM\u060c Medscape , Sep 15, 2026. | ESC 2026 \u2022\u2060 \u20601,803 intermediate-risk AF patients: CHA\u2082DS\u2082-VASc 1 in men or 2 in women \u2014: DOAC vs no anticoagulation; follow-up ~2 years. \u2022\u2060 \u2060Primary outcome: 0.5% vs 1.5%; ischemic stroke 3 vs 10; major [&hellip;]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-10583","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/10583","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=10583"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/10583\/revisions"}],"predecessor-version":[{"id":10584,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/10583\/revisions\/10584"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=10583"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=10583"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=10583"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}